According to TMR, the global pulmonary arterial hypertension therapeutics market is expected to reach a valuation of US$ 5.19 bn by the end of 2020. The global pulmonary arterial hypertension market is segmented based on drug class, which includes PDE-5 inhibitors, prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), soluble guanylate cyclase (sGC) stimulators and selexipag. Among these, prostacyclin and prostacyclin analogs are estimated to outgrow PAH market by the end forecast period. Geographically, North America is leading the global PAH market followed by Europe. Increasing awareness among the people for better availability of treatment for pulmonary arterial hypertension therapeutics has further fueled the market.
Request to View Sample of Report –
Launch of Innovative Treatment Therapies to Boost the Pulmonary Arterial Hypertension Therapeutic Market
Pulmonary hypertension occurs due to high blood pressure in arteries caused by shortness of breath, chest pain, fast heartbeat, tiredness, and syncope. By the help of certain treatments, it is possible to curb the progression of the disease, control its symptoms, and improve quality of life, thus increasing the demand for pulmonary arterial hypertension. The market is expected to gain impetus from the approval of new and effective drugs and the presence of effective regulatory measures. In addition, promising government initiatives and changing traditional norms are going to enhance and grow the development of the market. Moreover, innovative therapies used for treatments will accentuate growth for pulmonary arterial hypertension therapeutic market in the coming years.
Unsuccessful Clinical Trials and Slow Process in Drug Research and Development to Hamper Growth
The presence of generic medicines that are cost effective with the same proportion to medication can restrict the market. Excessive use of tobacco, smoking, high consumption of alcohol and idiopathic conditions have increased health risks in past few years. Furthermore, due to slow growth of research and development, that has increased cost of treatments and diagnosis, faulty drugs identified during clinical trials, and lack of awareness about pulmonary arterial hypertension will obstruct the growth of this market. Nonetheless, the pulmonary arterial hypertension therapeutic market is expected to overcome the limitations that will boost the market substantially during the forecast period.
Request PDF Brochure of Report:
A recent report by Transparency Market Research (TMR) on the global pulmonary arterial hypertension therapeutics market states that there is a huge amount of opportunity for the market to grow in the coming years. As there is no permanent treatment for pulmonary arterial hypertension (PAH) the market is expected to expand considerably by the end of 2020. Government initiatives in promoting research and development of orphan drugs has boosted the market for PAH. Approved certified agents producing therapeutics drugs will significantly grow the market in coming years. Some of the prominent players in the global market for pulmonary arterial hypertension are United Therapeutics Corp, Gilead Sciences Inc., GlaxoSmithKline Plc., Bayer HealthCare, Actelion Pharmaceuticals Ltd., and Novartis International AG, Pfizer Inc.
The information presented in this review is based on a TMR report, titled “Pulmonary Arterial Hypertension (PAH) Market (Drug Class – Prostacyclin and Prostacyclin Analogs, ERAs, PDE-5 Inhibitors, and sGC Stimulators; Pipeline Stage – Early-stage Drug Candidates (Phase I & Phase II) and Late-stage Drug Candidates (Phase III & Registration Phase)) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020.”
No comments:
Post a Comment